Understanding molecular mechanisms mediating epileptogenesis is critical for developing
more effective therapies for epilepsy. We recently found that the mammalian target of …

Traditionally, medical therapy for epilepsy has aimed to suppress seizure activity, but has
been unable to alter the progression of the underlying disease. Recent advances in our …

Purpose: The mammalian target of rapamycin (mTOR) pathway has been implicated in
contributing to progressive epileptogenesis in models of chronic epilepsy. Conversely …

mTOR is activated in epilepsy, but the mechanisms of mTOR activation in post-traumatic
epileptogenesis are unknown. It is also not clear whether mTOR inhibition has an anti …

Most current treatments for epilepsy are symptomatic therapies that suppress seizures but
do not affect the underlying course or prognosis of epilepsy. The need for disease‐modifying …

Despite a large number of available medical options, many individuals with epilepsy are
refractory to existing therapies that mainly target neurotransmitter or ion channel activity. A …

Inhibition of mTOR by rapamycin has been shown to suppress seizures in TSC/PTEN
genetic models. Rapamycin, when applied immediately before or after a neurological insult …

Several preclinical and some clinical studies have revealed that the mammalian target of
rapamycin (mTOR) signaling pathway is involved in both genetic and acquired epilepsy …

Epilepsy, a common neurological disorder and cause of significant morbidity and mortality,
places an enormous burden on the individual and society. Presently, most drugs for epilepsy …

Certain mutations within the mammalian target of rapamycin (mTOR) pathway, most notably
those affecting the tuberous sclerosis complex (TSC), lead to aberrant activation of mTOR …